<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107468">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01760863</url>
  </required_header>
  <id_info>
    <org_study_id>11040802</org_study_id>
    <nct_id>NCT01760863</nct_id>
  </id_info>
  <brief_title>Oral Antibiotics After 2-Stage Revision for Infected Total Hip Arthroplasty and Total Knee Arthroplasty</brief_title>
  <official_title>The Utility of Oral Antibiotic Therapy Following 2-stage Revision Arthroplasty for Infected Prosthetic Hips and Knees</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the re-infection rates in patients
      undergoing 2-stage revision arthroplasty who receive additional oral antibiotic therapy to
      those patients who received in-hospital perioperative antibiotic only. Patients will be
      monitored for re-infection following hospital discharge, defined as deep infection of the
      joint space/capsule that requires return to the operating room within 24-months of the
      re-implantation procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Infection Rate</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prosthesis-Related Infections</condition>
  <arm_group>
    <arm_group_label>Oral Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral antibiotics for 3 months; recommendation for antibiotics will be made by an infectious disease specialist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No oral antibiotics</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No oral antibiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Antibiotics</intervention_name>
    <description>Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.</description>
    <arm_group_label>Oral Antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Adult patients undergoing 2-stage revision arthroplasty of the knee or hip with the
        causative organism(s) identified using tissue culture and/or joint fluid analysis that is
        amenable to oral antibiotic therapy. Patients must be able to tolerate oral antibiotics
        and agree to participate in the study.

        Exclusion criteria:

        Patients with a fungal prosthetic joint infection, unable to tolerate or refuse to undergo
        oral antibiotic therapy, unable to follow-up at the specified intervals, allergic to the
        therapy of preference, or have an organism that is not amenable to oral antibiotic
        therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Craig J Della Valle, MD</last_name>
    <phone>3124322350</phone>
    <email>craigdv@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren R Plummer, MBA</last_name>
      <phone>312-432-2468</phone>
      <email>darren.plummer@rushortho.com</email>
    </contact>
    <contact_backup>
      <last_name>Craig J Della Valle, MD</last_name>
      <phone>312-432-2350</phone>
      <email>craigdv@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Craig J Della Valle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central DuPage Hospital</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott M Sporer, MD,MS</last_name>
      <email>scott.sporer@rushortho.com</email>
    </contact>
    <investigator>
      <last_name>Scott M Sporer, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javad Parvizi, MD</last_name>
      <email>parvj@aol.com</email>
    </contact>
    <investigator>
      <last_name>Javad Parvizi, MD, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zywiel MG, Johnson AJ, Stroh DA, Martin J, Marker DR, Mont MA. Prophylactic oral antibiotics reduce reinfection rates following two-stage revision total knee arthroplasty. Int Orthop. 2011 Jan;35(1):37-42. doi: 10.1007/s00264-010-0992-x. Epub 2010 Mar 7.</citation>
    <PMID>20213514</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 20, 2013</lastchanged_date>
  <firstreceived_date>January 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Craig J Della Valle</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Revision</keyword>
  <keyword>Knee</keyword>
  <keyword>Hip</keyword>
  <keyword>Arthroplasty</keyword>
  <keyword>Oral</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Infection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prosthesis-Related Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
